Serum Elastin-Derived Peptides and Anti-Elastin Antibody in Patients with Systemic Sclerosis Full Text
Journal of Korean Medical Science, 05/09/2012
Hong YJ et al. – The increased soluble elastin–derived peptide (S–EDP) and anti–elastin antibody levels and association with clinical and laboratory characteristics may reflect the abnormal metabolism in systemic sclerosis (SSc).Methods
- Serum samples were obtained from 79 patients with SSc and 79 age– and sex–matched healthy controls.
- Concentrations of serum S–EDP and anti–elastin antibodies were measured by ELISA.
- The serum concentrations of S–EDP in SSc patients were significantly higher than in healthy controls (median, 144.44 ng/mL vs 79.59 ng/mL, P < 0.001).
- Serum EDP concentrations were found to be correlated with disease duration in SSc (P = 0.002) and particularly in diffuse cutaneous SSc (P = 0.005).
- Levels of anti–elastin antibodies were found to be more elevated in SSc patients than in healthy controls (median, 0.222 U vs 0.191 U, P = 0.049), more increased in diffuse cutaneous SSc than limited cutaneous SSc (median, 0.368 U vs 0.204 U, P = 0.031).
- In addition, levels of anti–elastin antibodies were also found to be negatively associated with presence of anti–centromere antibody (P = 0.023).
- The S–EDP levels were not found to be correlated with levels of anti–elastin antibodies.